Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbinoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 8/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 5/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.62 |
| ▸ | HTR2A | P28223 | 4/20 | 0.62 |
| ▸ | SCN1A | P35498 | 4/20 | 0.62 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.62 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.62 |
| ▸ | HRH2 | P25021 | 3/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbinoxamine SCHEMBL29881788 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Rotoxamine SCHEMBL29485023 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Rotoxamine SCHEMBL141389 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL5070 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL8709373 | 0.99 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL662375 | 0.96 | CHRM2 (0.93) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL6626762 | 0.95 | CHRM2 (0.91) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL9095143 | 0.95 | CHRM2 (0.91) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL17685697 | 0.92 | CHRM2 (0.84) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL4074917 | 0.91 | CHRM2 (0.83) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247331-B1 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING AN ANTIHISTAMINE COMPOUND | BIOPHARMA SYNERGIES S L (ES) | 2025-10-08 | — | — | EP | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025264260-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4491193-A2 | ANTI-CD154 ANTIBODIES AND USES THEREOF | Tonix Pharma Limited (IE) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024263560-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-3993876-B1 | ANTI-CD154 ANTIBODIES AND USES THEREOF | TONIX PHARMA LTD (IE) | 2024-08-28 | — | — | EP | disclosed |
| CN-117835972-A | Novel compositions comprising immunomodulatory drugs | 南爱克萨股份公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20230148946-A1 | METHODS OF DETECTING ALLERGIC REACTIONS IN SUBJECTS USING MICROCHANNEL DELIVERY DEVICES | AQUAVIT PHARMACEUTICALS INC (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4178589-A1 | METHODS OF PROTECTING CELLS FROM INSULTS | Musc Foundation for Research Development (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-116063137-A | Synthesis method for synthesizing chiral 2-pyridyl aryl methanol by iridium catalysis | 中国科学院大连化学物理研究所 | 2023-05-05 | — | — | CN | disclosed |
| CN-115701989-A | Co-milled active-containing products comprising surface-reacted calcium carbonate | OMYA国际股份公司 | 2023-02-14 | — | — | CN | disclosed |
| US-20220380478-A1 | ANTI-CD154 ANTIBODIES AND USES THEREOF | TONIX PHARMACEUTICALS HOLDING CORP. | 2022-12-01 | — | — | US | disclosed |
| US-20220362404-A1 | MODULATION OF CELLULAR VIABILITY | MACQUARIE UNIVERSITY (AU) | 2022-11-17 | — | — | US | disclosed |
| EP-3993876-A1 | ANTI-CD154 ANTIBODIES AND USES THEREOF | Tonix Pharma Limited (IE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |